TY - JOUR
T1 - Extracellular vesicle omics assisted disease management
AU - Liu, Pan
AU - Zhuang, Wan Ru
AU - Sun, Jian
AU - Xie, Hai Yan
N1 - Publisher Copyright:
© 2025 Elsevier B.V.
PY - 2026/2
Y1 - 2026/2
N2 - Nanoscale vesicles released by cells mirror tissue and immune states across biofluids, offering a minimally invasive window into human disease. This review uses extracellular vesicle (EV) omics as a unifying thread and highlights the advantages of EVs across diagnosis, therapy, and prevention. On the diagnostic front, proteomics and metabolomics are proximal to pathology and responsive to temporal changes, enabling extraction of high-dimensional features from minimally invasive specimens that improve early screening, stratification, and pan-cancer detection. Therapeutically, drawing on stem cell and immune cell EV exemplars, integrated proteomics, metabolomics, and glycomics pinpoint effective cargo and key pathways and distill these into traceable critical quality attributes (CQAs) that inform source selection, process optimization, and patient stratification; in parallel, biomimetic EVs use omics data to guide their assembly and targeting, helping improve yield and consistency. Nature-derived vesicles, such as plant EVs and microbial outer membrane vesicles (OMVs), contribute to both preventive and therapeutic interventions, guided by omics profiling of their cargo and host responses. Finally, we outline a practical roadmap that harmonizes pre-analytics and orthogonal characterization, integrates multi-omics around a proteome and metabolome backbone, pairs external validation with decision analysis to establish clinical utility, and defines a minimal omics fingerprint, thereby moving EVs from concept to interpretable, reproducible, and deployable applications.
AB - Nanoscale vesicles released by cells mirror tissue and immune states across biofluids, offering a minimally invasive window into human disease. This review uses extracellular vesicle (EV) omics as a unifying thread and highlights the advantages of EVs across diagnosis, therapy, and prevention. On the diagnostic front, proteomics and metabolomics are proximal to pathology and responsive to temporal changes, enabling extraction of high-dimensional features from minimally invasive specimens that improve early screening, stratification, and pan-cancer detection. Therapeutically, drawing on stem cell and immune cell EV exemplars, integrated proteomics, metabolomics, and glycomics pinpoint effective cargo and key pathways and distill these into traceable critical quality attributes (CQAs) that inform source selection, process optimization, and patient stratification; in parallel, biomimetic EVs use omics data to guide their assembly and targeting, helping improve yield and consistency. Nature-derived vesicles, such as plant EVs and microbial outer membrane vesicles (OMVs), contribute to both preventive and therapeutic interventions, guided by omics profiling of their cargo and host responses. Finally, we outline a practical roadmap that harmonizes pre-analytics and orthogonal characterization, integrates multi-omics around a proteome and metabolome backbone, pairs external validation with decision analysis to establish clinical utility, and defines a minimal omics fingerprint, thereby moving EVs from concept to interpretable, reproducible, and deployable applications.
KW - Diagnostic markers
KW - Extracellular vesicle
KW - Omics
KW - Protein corona
KW - Translational nanomedicine
UR - https://www.scopus.com/pages/publications/105025551592
U2 - 10.1016/j.trac.2025.118621
DO - 10.1016/j.trac.2025.118621
M3 - Review article
AN - SCOPUS:105025551592
SN - 0165-9936
VL - 195
JO - TrAC - Trends in Analytical Chemistry
JF - TrAC - Trends in Analytical Chemistry
M1 - 118621
ER -